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Abstract
Background: To be useful, clinical practice guidelines need to be evidence based; otherwise they
will not achieve the validity, reliability and credibility required for implementation.
Methods: This paper compares the methods used in gathering, analysing and linking of evidence
to guideline recommendations in ten current hypertension guidelines.
Results: It found several guidelines had failed to implement methods of searching for the relevant
literature, critical analysis and linking to recommendations that minimise the risk of bias in the
interpretation of research evidence. The more rigorous guidelines showed discrepancies in
recommendations and grading that reflected different approaches to the use of evidence in
guideline development.
Conclusion: Clinical practice guidelines as a methodology are clearly still an evolving health care
technology.
Background
Clinical practice guidelines can provide building blocks
for changing and improving health care [1] and are a use-
ful means of bridging the gap between scientific research
evidence and usual practice [2]. They are defined as 'sys-
tematically developed statements to assist physicians and
patients about appropriate health care for specific clinical
circumstances' [3]. To achieve their potential as effective
tools for improving health care they need to maximise
their validity, a feature related to the use of evidence
within a guideline and development using a multidiscipli-
nary process [4]. However, despite an apparently explicit
methodology there are variations in what guidelines say
and how they relate this to underlying evidence [3,5,6].
There is also concern that guideline development may be
subject to external influence [7,8].
Like many other conditions hypertension has been the
subject of many different international guidelines. The
World Health Organisation (WHO) have described
hypertension – defined as a blood pressure of greater than
140/90 mmHg – as one of the ten leading risk factors
influencing the global burden of disease [9]. It is a con-
tributory factor in ischaemic heart disease and cerebrovas-
cular disease accounting for 20% and 10% of all deaths in
England and Wales respectively [10]. Reducing blood
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cular and cerebrovascular morbidity and mortality [11].
Nevertheless the management of hypertension remains
suboptimal: for example, 40% of the adult population of
England suffer from hypertension, but current levels of
detection and treatment result in only 9% of sufferers hav-
ing their hypertension controlled to <140/90 mm Hg
[12]. There is a clear need to improve the management of
hypertension both in this country and worldwide. If
guidelines, however, are to play a role in this improve-
ment they will need to maximise their validity.
The aim of this study was to review how well 10 guidelines
for hypertension addressed validity in terms of their meth-
ods and their use of published evidence.
Methods
Contributing guidelines
We reviewed the methods used in development and the
key recommendations of ten current guidelines (see table
1) meeting the following criteria: they concerned the gen-
eral management of hypertension, or the management of
hypertension in specific populations; published in Eng-
lish and nationally or internationally recognised. Guide-
lines developed before 1994 were also excluded as they
predated the publication and wide dissemination of the
work by Field and Lohr which offered the first and semi-
nal work on guideline methodology [1].
We used five guidelines (CMA [13], WHO [14], VHA [15],
ICSI [16], SA [17]) meeting these criteria retrieved by the
comprehensive search strategy employed by the German
Guideline Clearing Report [7], whose search strategy cov-
Table 1: Recent major guidelines for hypertension
Organisation Publication Year Acronym
Canadian Medical Association [13] 1999 CMA
World Health Organisation – International 
Society of Hypertension [14]
1999 WHO
Veterans Health Administration (US) [15] 2000 VHA
Scottish Intercollegiate Guidelines Network 
[18]
2001 SIGN
European Society of Hypertension[19] 2003 ESH
Institute for Clinical Systems Improvement 
(US) [16]
2003 ICSI
Joint National Committee VII (US) 2003 JNC
Southern African Hypertension Society [17] 2003 SA
British Hypertension Society [21] 2004 BHS
National Institute for Clinical Excellence [22] 2004 NICE
Table 2: Methodological aspects of recent major guidelines for hypertension
Guideline Development 
group 
describeda
New systematic 
reviewing
Used existing 
systematic 
reviewsc
Literature 
searchb
Grading of evi-
denced
Grading of rec-
ommendationsd
CMA P N Y Y Y Y
WHO P N Y N N N
VHA P N N Y Y Y
SIGN Y N Y Y Y Y
ESH Y N Y N N N
ICSI N N y N Y N
JNC P N Y N Y N
SA P N y N N N
BHS P N Y N Y Y
NICE Y Y Y Y Y Y
a Y/N: Includes/does not include description of stakeholders involved in the development process, including patient representatives and any 
conflicts of interest.
P: Partially – a list of names with institutional affiliations was provided.
b Y/N: Searches were/were not undertaken, at least through Medline.
c Y: Made extensive use of existing systematic reviews (referenced 7 or more).
y: Made partial use of existing systematic reviews (referenced 6 or less).
N: Did not use existing systematic reviews.
d Y/N: Reports/does not report explicit grading of the quality of the supporting evidence/recommendations.Page 2 of 16
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Guideline Literature search Grading of evidence Development group
CMA MEDLINE and Cochrane 
Collaboration searches; reference 
lists in retrieved articles. Requests 
to experts and panel members.
Recommendations were graded 
from A-D and were based on 
assessment of the studies using an 
algorithm.
A Grade assigned if 
recommendation was:
– based on an adequate RCT ie, 
with blinded assessment of 
outcomes, intention-to-treat 
analysis, adequate follow-up, and 
sufficient sample size to detect a 
clinically important difference with 
power greater than 80%.
– based on an adequate subgroup 
analysis
– based on a systematic review in 
which the comparison arms are 
derived from head-to head 
comparisons with the same RCT
A committee with a range of 
representatives from different 
bodies. Patient involvement unclear
WHO None described None described Patient involvement unclear
VHA MeSH terms covering key therapies, 
and study characteristics and design
Evidence was graded:
A RCT
B well-designed clinical studies
C panel consensus
Recommendations were rated:
I usually indicated; always 
acceptable; useful and effective
IIa acceptable, of uncertain 
effectiveness, and may be 
controversial. Weight of evidence 
in favour of usefulness/effectiveness
IIb acceptable, of uncertain 
effectiveness and may be 
controversial. Not well established 
by evidence, can be helpful and 
probably not harmful
Thirty-eight individuals. Roles not 
always clear.
SIGN Systematic literature searches on 
MEDLINE, Healthstar, EMBASE, 
Cochrane Library. Based on a 
published Cochrane review
Evidence was graded when obtained 
from:
Ia: meta-analysis of RCTs Ib: at least 
1 RCT
IIa: at least 1 well-designed 
controlled study without 
randomisation
IIb: at least one other type of well-
designed quasi-experimental study
III: well-designed non-experimental 
descriptive studies
IV: expert committee reports and/
or respected clinical opinion
Recommendations were rated:
A Evidence levels Ia, Ib
B Evidence levels IIa, IIb, III
C Evidence level IV.
Members' names and affiliations 
listed and conflicts of interest 
available. Specialist reviewer names 
given. Age Concern represented.
ESH None described Recommendations not classified 
upon strength of available evidence.
Members' names, affiliations, 
potential conflicts of interest given. 
Patient involvement unclearPage 3 of 16
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follows:
Primary reports A (RCT) to D 
(case and cross sectional studies)
Reviews M (Meta-analysis, 
systematic reviews, decision 
analysis, cost-benefit analysis, cost-
effectiveness study)
R: Narrative review, consensus 
statement or report
X: Medical opinion
In the 2002 update, some 
recommendations link to the 
evidence grade
No details
JNC None described Evidence supporting 
recommendations for prevention 
and treatment was classified:
M meta-analysis
Re retrospective analyses (case 
control)
RA RCT
F prospective follow-up – cohort 
study
Pr previous review
C clinical interventions (non-
randomised)
X cross-sectional population 
studies (prevalence)
Nine individuals. Contributions 
were sought from multidisciplinary 
experts. No mention of patient 
involvement
SA None described Evidence not described or graded Members' names and affiliation 
given. Patient involvement unclear
BHS Not described Strength of evidence: Ia (meta 
analysis of RCTs) to IV expert 
opinion Strength of 
recommendation
A Directly based on category I 
evidence
B Directly based on category II 
evidence or extrapolated 
recommendation from category I 
evidence
C Directly based on category III 
evidence or extrapolated 
recommendation from category I or 
II evidence.
D Directly based on category IV 
evidence or extrapolated 
recommendation from category I, II 
or III evidence
No details given
NICE Search using MEDLINE, EMBASE 
and CENTRAL, previous systematic 
reviews, bibliographic seachs as well 
as contact with subject area 
experts.
Guideline Recommendation and 
Evidence Grading (GREG [34]) 
system applied.
Evidence Grade: Interpretation 
of Evidence
I High Plausible, precisely quantified 
and not vulnerable to bias.
II Intermediate Plausible but not 
quantified precisely or may be 
vulnerable to bias.
III Low Concerns about plausibility 
or vulnerability to bias.
Recommendation Grade 
Interpretation of 
recommendation
A Recommendation Robust 
evidence
B Provisional Recommendation 
Recommend with caution
C Consensus Opinion 
Recommended by consensus
Members names and affiliations 
given and any potential conflicts of 
interest. Contributions were sought 
from multidisciplinary experts. 
Group included patient 
representatives
Table 3: Methodological aspects of previously published guidelines (Continued)Page 4 of 16
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MEDLINE, EMBASE and OMNI from 1999 onwards using
the thesaurus heading HYPERTENSION and limiting to
guidelines or practice guidelines in English. This retrieved
a further five guidelines (SIGN [18], ESH [19], JNC [20],
BHS [21], NICE [22]) for consideration.
Evaluation of guideline development methods
We evaluated the methods used to develop each guideline
with particular reference to three dimensions that relate to
the use of research evidence, as found in the full published
report of each guideline:
• the construction of the guideline development group
and its component stakeholders.
• the use of published literature and the strategy used in
screening for the primary evidence; in particular, the use
of existing systematic reviews or the performance of a new
systematic review explicitly to answer questions posed by
the guideline.
• the grading of evidence and recommendations: in par-
ticular, an explicit link between recommendations and
supporting evidence.
Evaluation of recommendations and their underlying 
evidence
We compared recommendations on four areas that were
common to all the guidelines: diagnosis of hypertension,
lifestyle modification, criteria for initiation of antihyper-
tensive drug therapies and initial recommended drug
therapy. We also explored links between recommenda-
tion grades and citations and looked at how these differed
in recommendations for drug therapy and salt intake.
Results
Methods used to develop the guidelines
The measures used to assess the guideline development
process are summarised in table 2.
Only three guidelines were constructed by multidiscipli-
nary groups where the members' affiliations and conflicts
of interest were described; these three guideline groups
included patient representatives as well as key profes-
sional stakeholders. A further six guidelines provided only
a list of names and institutional affiliations of members of
the guideline development group. One further guideline
gave no details of the guideline development group (see
table 3).
Only one guideline conducted new systematic reviews to
inform recommendations. Seven guidelines made exten-
sive use of existing systematic reviews; three of these
guidelines also stated that a search strategy based on
MESH search terms was used for identifying relevant
research evidence. A further two guidelines made limited
use of existing systematic reviews.
There were different approaches used in the guidelines to
assess the evidence available upon which to base a recom-
mendation and upon the grading of the recommendation
itself (see table 3 for a description of the grading systems
used in the guidelines). Three guidelines did not grade
either the evidence they cited or their recommendations.
Two coded the evidence on the basis of study design but
did not link this to the recommendations. In contrast, five
guidelines graded the evidence and explicitly linked this
to the recommendations. However, there were differences
also between these grading systems with different criteria
used to assess the contributing studies. The grading sys-
tems used by two guidelines (NICE, CMA) allowed for the
quality of relevant randomised controlled trials and meta-
analyses and the strength of their results to be analysed.
The grading systems used by other guidelines did not
allow for this more sensitive assessment of the evidence.
Differences and shortcomings in these grading systems
can be confusing and impede effective communication
[23]. The GRADE system was developed as a result of
these shortcomings and recommends an approach which
takes into account study design, quality, consistency and
directness in judging the considers the benefit harm ratio,
quality of evidence, applicability, and baseline risk when
translating to recommendation [23].
Recommendations made by the guidelines
Diagnosis of hypertension
The guidelines were consistent in defining the threshold
for hypertension as 140/90 mmHg and all agreed that
blood pressure should be measured twice in a consulta-
tion on at least two separate occasions. The need for a full
medical examination, clinical history and accurate blood
pressure measurement was described in all of the guide-
lines. However, they differed on the recommended rou-
tine tests. All agreed that an electrocardiogram, blood
chemistry, a complete blood cell count and urinalysis
should be conducted during the initial assessment of
hypertension, to assess broader cardiovascular risk. There
was less agreement on the assessment of: total cholesterol,
lipid profile, blood glucose, creatinine, blood calcium,
thyroid stimulating hormone, gammaglutamyl
transpeptidase and serum urate.
Lifestyle modifications
All of the guidelines addressed lifestyle modification as an
integral part of the management of hypertension and as a
first line treatment in mild hypertension, and made simi-
lar recommendations for weight loss, limiting alcohol and
sodium intake, regular exercise and smoking cessation
(see table 4). Guidelines typically recommended a targetPage 5 of 16
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Table 4: Recommendations for lifestyle interventions in recent major guidelines for hypertension
Guideline Weight reduction Diet Salt restriction Alcohol restriction Smoking 
cessation
Exercise
Recommended weight Reduce saturated 
fat
Increase fruit & 
vegetables
Other 
recommendations
Recommended max. 
daily intake
Recommended max. 
daily intake (ethanol)
CMA Y
(BMI 20–25 kg/m2)
No specific recommendation Y
(3–7 g/day)
≤17.4 g/day (women)
≤27.0 g/day (men)
Y 50–60 mins. aerobic 
exercise 3–4 times per 
week
WHO Y if overweight Y Y Increase fish 
consumption
Y
(≤ 6 g/day)
≤10–20 g/day (women)
≤ 20–30 g/day (men)
Y 30–45 mins. aerobic 
exercise 3–4 times /
week
VHA Y
(if > 10% of ideal body weight)
Y Y Increase cereal 
consumption
Y
(≤ 6 g/day)
≤14 g/day (women)
≤ 28 g/day (men)
Y 30–45 mins. aerobic 
exercise 3–5 times/
week
SIGN Y
(BMI < 25 kg/m2)
Y Y Y
(<5 g/day)
≤15.8 g/day (women)
≤ 23.7 g/day (men)
Y 30–45 mins. aerobic 
exercise most days
ESH Y Y Y Increase fish 
consumption
Y
(4.7–5.8 g/day)
≤10–20 g/day (women)
≤ 20–30 g/day (men)
Y 30–45 mins. aerobic 
exercise 3–5 times/
week
ICSI Y if overweight Y Y Increase low fat 
dairy food 
consumption
Y
(<6 g/day)
≤14 g/day (women)
≤ 28 g/day (men)
Y 30–45 mins. aerobic 
exercise 3–4 times/
week
JNC Y
(BMI 18.5–25 kg/m2)
Y Y Increase low fat 
dairy food 
consumption
Y
(≤ 6 g/day)
≤14 g/day (women)
≤ 28 g/day (men)
Not 
discussed
≥30 mins. aerobic 
exercise most days
SA Y
(BMI < 25 kg/m2)
Y Y Increase fibre, 
unrefined 
carbohydrates
Y ≤24 g/day Y 30 mins. aerobic 
exercise 3–5 times per 
week
BHS Y
(BMI 20–25 kg/m2)
Y Y Reduce total fat Y
(< 6 g/day)
≤15.8 g/day
≤ 23.7 g/day (men)
Y > 30 mins. aerobic 
exercise most days
NICE Y Healthy, low calorie diet Y
(<6 g/day)
< 14 units/wk (women)
< 21 units/week (men)
Y 30–60 mins. 3–5 times/
week
BMC Health Services Research 2006, 6:47 http://www.biomedcentral.com/1472-6963/6/47BMI of 18.5 – 25 kg/m2, restriction of salt intake to under
6 g/day and restriction of alcohol to 14 to 20 g (ethanol)
per day for women and from 24 to 30 g (ethanol) per day
for men. Differences in the daily limits for alcohol con-
sumption may reflect the variations on guidance for sen-
sible drinking in different countries. Most guidelines
recommended a diet rich in fruit and vegetables with
reduced saturated and total fats. Guidelines typically rec-
ommended 30–45 minutes of aerobic exercise three to
five times per week. Although their recommendations
were similar, guidelines lacked consistency in the estima-
tions of the effect of lifestyle changes on blood pressure,
possibly reflecting the different data sources used. Guide-
lines varied in the additional areas that they addressed:
potassium, magnesium and calcium supplementation,
management of stress and caffeine consumption were
considered by some of the guidelines. This demonstrates
one of the challenges facing guideline developers. Each
clinical care pathway involving assessment, diagnosis,
treatment and follow-up requires multiple complex deci-
sions. A clinical guideline will be unable to offer guidance
on every consideration that must be made by caregivers
and patients. Guidelines will reflect this complexity and
are likely to vary in their scope and coverage of the deci-
sions involved in the care pathway.
Criteria for initiation of antihypertensive drug therapy
Guidelines used a varying combination of blood pressure
and other factors to establish a threshold for drug therapy
(see Table 5). These factors included the presence of con-
comitant disease, target organ damage, cardiovascular risk
factors, response to lifestyle changes and the patient's own
personal preferences. For uncomplicated patients the rel-
atively recent SA and JNC guidelines recommended lower
thresholds. All guidelines (except CMA) recommended
lower thresholds for patients with target organ damage,
renal disease or diabetes. Some guidelines modified their
recommendations for older age groups and specific ethnic
groups.
Table 5: Recommended thresholds for drug treatment and initial drug therapy in recent major guidelines for hypertension
Thresholds for initiating drug treatment* Initial drug therapy in 
uncomplicated patient (non-black 
patient aged over 55–60 years)†
Guideline No target organ 
damage or risk 
factors
With risk factors 
(other than diabetes 
mellitus)
With target organ 
damage
With diabetes 
mellitus or renal 
disease
Recommendation Grade of 
recommendation
CMA ≥160/90 ≥160/90 ≥160/90 ≥140/90 Thiazides A
WHO ≥150/95 ≥140/90 ≥140/90 ≥130/85 Low dose 
monotherapy
VHA >160 and/or>100 >160 and/or >100 ≥130/85 ≥130/85 Thiazides or β-
blockers
SIGN ≥160/100 ≥160/100 ≥140/90 ≥140/90 Thiazides A
ESH ≥150/95 ≥140/90 ≥130/85 ≥130/85 Low dose 
monotherapy or a 
combination
ICSI ≥160/100 ≥140/90 ≥130/85 ≥130/85 Thiazides
JNC ≥140/90 ≥140/90 ≥130/80 ≥130/80 Thiazides alone 
and/or 
combination ACE, 
ARB, β-blockers, 
CCB
SA ≥140/90 ≥140/90 ≥130/85 ≥130/85 Thiazides
BHS ≥160/100 ≥140/90 ≥140/90 ≥140/90 Thiazides or 
calcium channel 
blockers
C
NICE ≥160/100 ≥160/100 or ≥ 
140/90 if CHD§ 
risk ≥ 15% or 
CVD¶risk ≥ 20%
≥140/90 Outside scope of 
guideline
Thiazides A[34]
* Blood pressure threshold in mmHg
† Thiazides: low dose thiazide diuretics
ACE: angiotensin-converting enzyme inhibitors
ARB: angiotensin receptor blockers
CCB: calcium channel blocker
§CVD: cardiovascular disease
¶CHD: coronary heart diseasePage 7 of 16
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Variations existed in thresholds for initiating drug treat-
ment and initial drug therapy in typical patients (table 5).
Five guidelines recommended the use of thiazdes as initial
therapy in non- black patients aged over 55–65 years
(SIGN, CMA, ICSI, SA, NICE). The other five differed in
their recommendations, one recommended thiazides or
b-blockers (VHA), one recommended low dose mono-
therapy selecting from a broad range of antihypertensive
agents (WHO), one recommended low dose mono-
therapy or a combination of low dose antihypertensive
agents (ESH), one recommended thiazides or calcium
channel blockers (BHS) and one recommended thiazides
alone or in combination with a range of antihypertensive
drugs (JNC). The pattern of variation in these recommen-
dations did not follow publication date of the guideline or
relate to the research sources used in the development of
the guideline.
Grading recommendations and links to the evidence base
Salt intake
Although all guidelines recommended restriction of salt
intake, four (SIGN, CMA, BHS, NICE) relied upon a simi-
lar and extensive body of work, either directly using the
original data in a systematic review or indirectly sourcing
the study via a previously published systematic review
(see table 6). Nevertheless, these four guidelines were
inconsistent in their grading of the recommendation: two
guidelines (CMA, NICE) graded it 'B' suggesting that the
pattern of care was recommended with caution and based
upon research evidence subject to bias, while two graded
it as 'A' (BHS, SIGN) indicating that the recommendation
was based on strong research evidence not vulnerable to
bias. Although the VHA guideline cited much less evi-
dence than these four guidelines, it nevertheless graded
salt restriction as 'I', equivalent to 'A' in other schemes.
These disparities reflects the differences in the grading of
recommendations in guideline development. Both the
CMA and NICE guidelines adopted systems that required
judgement about the quality of the RCT and the strength
of its findings rather than a system that graded recommen-
dations solely upon research design. The other five guide-
lines made similar recommendations about salt
restriction, although they cited very limited evidence to
support this.
Table 6: Reporting in guidelines of trials and systematic reviews of salt reduction
Referen
ce
Year CMA 
1999
WHO 
1999
VHA 
1999
SIGN 
2001
ESH 
2003
ICSI 
2003
JNC 
2003
SA 2003 BHS 
2004
NICE 
2004
Randomised Controlled Trials
Silman 
[35]
1983 Y SR[36] Y
Fagerberg 
[37]
1985 SR[38] SR[38] SR[38] Y
Chalmers 
[39]
1986 SR[38] SR[40] SR[38] SR[38] Y
Chalmers 
[41,42]
1989 SR[40] Y
TOHPI 1992 Y Y(ex)
Jula [43] 1994 SR[38] SR[38] SR[38] Y
Whelton 
[44]
1998 Y Y Y(ex)
Appel 
[45]
2001 Y Y(ex)
Sacks 
[46]
2001 Y Y Y(ex)
Systematic Reviews
Law [47] 1991 Y Y Y
Midgely 
[38]
1996 Y Y Y Y
Cutler 
[40]
1997 Y Y Y
Hooper 
[36]
2002 Y Y
Grade of recommendation
B I A - - - - A B[34]
Y Trial cited by guideline
SR Trial included in systematic review cited by guideline
Y(ex) Trial cited by guideline but excluded from meta-analysisPage 8 of 16
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Triala Yearb CMA 1999 WHO 
1999
VHA 
1999
SIGN 
2001
ESH 
2003
ICSI 
2003
JNC 
2003
SA 2003 BHS 
2004
NICE 
2004
VA-II[48] 1970 SR[49, 50] SR[49,51] SR[49,51,
52]
SR[51] SR[53] SR[51] SR[49]
HSCSG[5
4]
1974 SR[50] SR[51] SR[51] SR[51] SR[53] SR[51]
USPHS[55
]
1977 SR[50] SR[51] SR[51] SR[51] SR[53] SR[51]
VA-
NHLBI[56
]
1978 SR[50] SR[51] SR[51] SR[51] SR[53] SR[51]
HDFP[57-
59]
1979 SR[49] SR[49,51] SR[49,51,
52,60]
SR[51,61] SR[51] SR[49]
ANBPS[6
2]
1980 SR[51] SR[51,52,
60]
SR[51,63] SR SR[51]
EWPHE[6
4,65]
1985 SR[49,50] SR[49,51,
66]
SR[51,61] SR[53] SR[51] SR[49]
IPPPSH[6
7]
1985
MRC[68] 1985 SR[50] SR[51] SR[53] SR[51]
Coope[69
]
1986 SR[49] SR[49,51,
66]
SR[51,61] SR[53] SR[51] SR[49]
OSLO[70
]
1986 SR[50] SR[51] SR[51] SR[51] SR[53] SR[51]
SHEP-
P[71-73]
1986 SR[50] SR[60] SR[61] SR[53]
HAPPHY[
74]
1987 SR[50]
MAPHY[7
5]
1988
CAPPP[7
6,77]
1990
SHEP[78-
81]
1991
STOP-
H[82]
1991 SR[49] SR[61] SR[53] SR[49]
SYST-
EUR[83-
86]
1991 SR[87]
MRC-
O[88]
1992 SR[50] SR[61] SR[53] SR[49]
STOP-
H2[89-91]
1993 SR[92] SR[63,87,
93]
NICS-
EH[94,95]
1994 SR[92] SR[63,87,
93]
SR[63,96]
HOT[97] 1995
PATS[98] 1995
ALLHAT[
99,100]
1996
MIDAS[1
01,102]
1996 SR[50,92] SR[63]
VHAS[10
3]
1997 SR[50,92] SR[3,87,9
3]
SR[63,96]
?
?
?
?
? ? ?
?
? ?
? ? ?
? ? ?
? ?
?
?
? ?
?
? ? ? ? ? ?
? ? ? ? ? ? ?
? ? ? ?
? ? ? ? ? ?
? ? ? ?
? ? ? ?
?
? ? ? ? ? ? ? ? ?
? ?
? ? ? ? ?
? ? ?
? ?Page 9 of 16
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Overall the guidelines were relatively consistent in the
studies that they cited as the evidence for the drug treat-
ment recommendations (Table 7). One guideline (VHA)
cited very little evidence; another (ICSI) did not cite any
systematic reviews but referred to recent primary reports
of trials, two guidelines (CMA, SA) relied almost exclu-
sively on existing systematic reviews, whereas others
(WHO, SIGN, ESH, JNC, BHS) supplemented citation of
systematic reviews with citation of recent primary reports;
one guideline (NICE) performed its own systematic
review. Recommendations for use of thiazides and/or
beta-blockers as initial drug therapy in typical patients
were graded as 'A' by three guidelines (NICE, SIGN and
CMA). One guideline (BHS) recommended thiazides or
calcium channel blockers grading it 'C'. This recommen-
dation was largely based on the ABCD algorithm which in
turn is based upon an extrapolation of how different
drugs work rather than RCT findings; hence the evidence
was graded as category III (descriptive studies, or evidence
extrapolated from RCTs or quasi experimental studies),
leading to the grade of 'C' for the recommendation.
Discussion
Current guidelines are inconsistent in their handling of
key methodologies that relate to the sourcing, interpreta-
tion and application of research evidence. Some cite a
substantial body of evidence whereas others present little
evidence. Some grade their recommendations – although
the grading systems and grades used are not consistent –
whereas others do not. These findings are consistent with
other studies exploring the quality of guideline develop-
ment [24-27]. Methodological failings may affect the
quality of the guideline in several ways. A search that is
insufficiently thorough may introduce bias into the sum-
mary of the evidence [28]. Systematic reviews have been
described as the optimum method of summarising evi-
dence of effectiveness within a clinical practice guideline
[29]. In this study we found that most of the guidelines
relied on previously published systematic reviews, despite
ABCD[10
4]
1998 SR[92] SR[87]
FACET[1
05]
1998 SR[92]
UKPDS[1
06]
1998
HOPE[10 2000
INSIGHT[
108,109]
2000 SR[92]
NORDIL[
110]
2000 SR[92]
IDNT[111
]
2001 SR[93] SR[96]
PROGRE
SS[112]
2001
c
RENAAL[
113]
2001
ELSA[114 2002 SR[93] SR[96]
LIFE[115] 2002
ANBP2[1
16,117]
2003 SR[93] SR[96]
CONVIN
CE[118,1
19]
2003 SR[96]
SCOPE[1
20]
2003 SR[96]
JMIC- 2004 SR[96]
VALUE[1
22-124]
2004
a Trials post-dating the guidelines (indicated by the stepped line) were not available to the guideline developers.
b Year of earliest publication.
c Referred only to rationale and design.
 Primary report of trial cited by guideline.
SR Trial included in systematic review cited by guideline; primary report not cited by guideline.
Table 7: Reporting in guidelines of trials of antihypertensive medication a (Continued)
? ? ? ?
?
? ? ? ? ? ? ? ?
? ? ? ? ? ? ?
? ? ?
? ? ?
?
? ? ? ? ? ? ?
? ?
? ? ? ?
? ?
? ? ?
? ?
?
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atic reviews may date quickly and not incorporate newer
evidence. Secondly, the scope of the published reviews
may not always match the remit of the guideline and so
may not be relevant to the target population of the guide-
line. Thirdly, up-to-date high quality systematic reviews
may not be available in all the areas covered by a guide-
line.
Despite the inconsistent approach in the guidelines to
sourcing the evidence, interpreting it and applying it to
recommendations, and the great variation in the volume
of supporting evidence cited, the areas of consensus are
substantial. Different hypertension guidelines made simi-
lar recommendations for many areas of management,
notably recommendations for lifestyle changes and their
role as first line interventions for patients in certain cate-
gories of risk. This level of agreement suggests the possi-
bility either that the published guideline did not cite all
the evidence which influenced the recommendations, or
that guideline groups may develop guidelines that are
heavily influenced by previously published guidelines or
an implicit international consensus. Guidelines generated
without a systematic search of the literature and without
systematic review of all the supporting evidence would be
more likely to reflect the biases of developers and it would
not be surprising if they were congruent with other guide-
lines in the same area.
Only five guidelines graded the recommendations made.
Failure to grade research evidence and the subsequent rec-
ommendations means that the decision making process is
not explicit and does not inform the guideline user of the
strength of evidence underpinning a particular pattern of
care.
The inconsistent grading of the same recommendation in
different guidelines also indicates varying approaches to
interpreting and applying research evidence in guideline
development. The process of evaluating the quality of
research evidence and applying this to guideline recom-
mendations using a system of grading is clearly inconsist-
ent and currently an evolving area of guideline
methodology.
As well as seeking research evidence, guidelines seek to
elicit and incorporate the views of clinical experts and var-
ious stakeholders in interpreting the evidence or in offer-
ing expert opinion where objective evidence is sparse.
Indeed this is an important feature used to assess the qual-
ity of a guideline [30]. Differences in guidelines, reflecting
the differing views of individuals participating in the
guideline development process, are therefore to be
expected [29,31]. Herein lies a tension between the rigour
needed to try and produce objective and unbiased state-
ments and to also be responsive to the views of partici-
pants. It is clear from other reviews of clinical guidelines
that the composition of the development group is
reflected in the recommendations. Savoie et al [31] in
their critical appraisal of guidelines for cholesterol testing
found that the greater the involvement of clinical experts
in the development process of the guideline, the less the
recommendations reflected the research evidence. As only
three of the guidelines which we considered fully reported
the composition of the guideline development group, it is
not possible to make inferences about its impact on rec-
ommendations for hypertension. Achieving evidence
based guidelines while incorporating the views of the var-
ious stakeholders within the development group may cre-
ate conflict and divergence that the final guideline may
mask. The differences between the guidelines described
here may reflect this tension.
Differences in recommendations may reflect not only dif-
ferences in material sourced, differences in interpreting
and grading the evidence but also different influences in
moving from evidence to recommendations. Differing
recommendations for first line drug therapy suggest this.
The research base underpinning the recommendations for
first line drug therapies is strong in terms of the number
and quality of trials in the area (see table 6). Nevertheless,
three guidelines (NICE, SIGN and CMA) recommended
thiazides for the uncomplicated patient, grading this as
'A', while one (BHS) recommended thiazides or calcium
channel blockers grading it 'C'. This suggests either a
strong competing interest or the possibility that a less sup-
ported but broader recommendation is felt to hold greater
clinical merit than older treatments which have accumu-
lated a strong research base. This again may reflect a ten-
sion in the development of guidelines, between the
restrictiveness of the conventional evidence based
approach which inevitably relies on older, well researched
therapies and the greater openness of an approach which
allows newer, less well endorsed treatments.
Clinical guidelines are rarely based solely on the research
evidence and incorporate the consensus views of experts.
Raine et al. argue that current approaches to guideline
development often lack a sufficient transparency and reli-
ability concerning how such consensus opinions are
formed [32]. They highlight the possible influence of key
individuals, unrepresentative decision making and the
role of constraints of time and resources which limit the
range of guidelines that can be generated and their need
for updating. They propose an approach which makes rea-
sons for disagreement and degree of consensus explicit
and suggests the inclusion of a survey stage to enhance
reliability.Page 11 of 16
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tion of guideline recommendations highlights the need
for transparency in the declarations of conflictions of
interest by authors of clinical practice guidelines. One
investigation of panels that write clinical guidelines found
that more than one-third of authors declared financial
links to relevant drug companies, with around 70% of
panels being affected [33]. Another study found that 87%
of authors of clinical practice guidelines had some form of
interaction with the pharmaceutical industry [7]. If
authors have relationships that pose a potential conflict of
interest these need appropriate disclosure so that readers
may evaluate the merit of those guidelines.
Conclusion
Many challenges exist to improve the use of evidence in all
its forms in guideline development. Clinical practice
guidelines remain a developing healthcare technology
and if they are to fulfil their potential as a tool to improve
standards of care these challenges need to be addressed.
The requirements of future guidelines are clear if they are
to inform clinicians and patients about appropriate
healthcare. Authoritative and rigorously developed guide-
lines should (where possible) feature transparent and
fully reported: guideline group methods and participa-
tion; involvement of stakeholders and sponsors; reporting
and use of evidence and linking of recommendation to
evidence; understanding of health care delivery, the policy
context and narratives of patient experience.
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